Plans to recommence enrolment in the ACTIVATE clinical trial and new trial in pancreatic cancer in the US. OSLO/LONDON: 18 NOVEMBER, 2021: Exact Therapeutics AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX), a clinical-stage precision health company evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces a number of strategic, operational and scientific […]
A quarter of deal making and regulatory review “Following on from the positive top line read out of Part A our Phase 3 study, we initiated a structured process to select our commercial partner for Nefecon in Europe. In this case, the result of the process was a partnership with Stada Arzneimittel, which has proven […]
Incubated and supported by Denmark’s largest biotech investors, Lundbeckfonden and Novo Holdings Lundbeckfonden co-led the Series A financing in 2015 together with Novo Holdings, and is the largest shareholder Novo Holdings created and launched IO Biotech with first seed investment in 2015 Copenhagen, Denmark – 9 November 2021 – Novo Holdings, a leading international life science investor, […]
Asgard Therapeutics developing in vivo immune cell reprogramming technology to reinstate cancer immunogenicity Funds will be used to further develop off-the-shelf and personalized therapy programs for multiple oncology indications Novo Holdings co-led the financing with Boehringer Ingelheim Venture Fund and Industrifonden Copenhagen, Denmark – Novo Holdings, a leading international life science investor, today announces that it […]
Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021 ENHANCE Phase 3 program on track to report top-line data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), […]
